RCUS Arcus Biosciences, Inc.
P/E
--
Forward P/E
--
Price/Sales
19.33
Beta
0.938
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Arcus Biosciences third quarter 2026 revenue of $9M beats while casdatifan Phase 3 trials accelerate
Arcus Biosciences reported third quarter revenue of $9 million, exceeding expectations despite a significant year-over-year decline as Gilead collaboration...
Arcus Biosciences Inc Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
Arcus Biosciences is expected to report Q3 2026 revenue of $7.58 million and a consensus EPS loss of -$0.92, with the stock currently trading at approximately...